These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37385888)

  • 21. Durability of the Single-Dose Ad26.COV2.S Vaccine in the Prevention of COVID-19 Infections and Hospitalizations in the US Before and During the Delta Variant Surge.
    Polinski JM; Weckstein AR; Batech M; Kabelac C; Kamath T; Harvey R; Jain S; Rassen JA; Khan N; Schneeweiss S
    JAMA Netw Open; 2022 Mar; 5(3):e222959. PubMed ID: 35297969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
    Voysey M; Clemens SAC; Madhi SA; Weckx LY; Folegatti PM; Aley PK; Angus B; Baillie VL; Barnabas SL; Bhorat QE; Bibi S; Briner C; Cicconi P; Collins AM; Colin-Jones R; Cutland CL; Darton TC; Dheda K; Duncan CJA; Emary KRW; Ewer KJ; Fairlie L; Faust SN; Feng S; Ferreira DM; Finn A; Goodman AL; Green CM; Green CA; Heath PT; Hill C; Hill H; Hirsch I; Hodgson SHC; Izu A; Jackson S; Jenkin D; Joe CCD; Kerridge S; Koen A; Kwatra G; Lazarus R; Lawrie AM; Lelliott A; Libri V; Lillie PJ; Mallory R; Mendes AVA; Milan EP; Minassian AM; McGregor A; Morrison H; Mujadidi YF; Nana A; O'Reilly PJ; Padayachee SD; Pittella A; Plested E; Pollock KM; Ramasamy MN; Rhead S; Schwarzbold AV; Singh N; Smith A; Song R; Snape MD; Sprinz E; Sutherland RK; Tarrant R; Thomson EC; Török ME; Toshner M; Turner DPJ; Vekemans J; Villafana TL; Watson MEE; Williams CJ; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
    Lancet; 2021 Jan; 397(10269):99-111. PubMed ID: 33306989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial.
    Marchese AM; Zhou X; Kinol J; Underwood E; Woo W; McGarry A; Beyhaghi H; Áñez G; Toback S; Dunkle LM
    Vaccine; 2023 May; 41(22):3461-3466. PubMed ID: 37127523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. COVID-19 Vaccine-Associated Uveitis in Patients With a History of Uveitis.
    Kim J; Kwon HY; Ahn SJ
    JAMA Ophthalmol; 2024 Jun; 142(6):522-528. PubMed ID: 38662361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measuring Vaccine Efficacy Against Infection and Disease in Clinical Trials: Sources and Magnitude of Bias in Coronavirus Disease 2019 (COVID-19) Vaccine Efficacy Estimates.
    Williams LR; Ferguson NM; Donnelly CA; Grassly NC
    Clin Infect Dis; 2022 Aug; 75(1):e764-e773. PubMed ID: 34698827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial.
    Madhi SA; Moodley D; Hanley S; Archary M; Hoosain Z; Lalloo U; Louw C; Fairlie L; Fouche LF; Masilela MSL; Singh N; Grobbelaar C; Ahmed K; Benadé G; Bhikha S; Bhorat AE; Bhorat Q; Joseph N; Dheda K; Esmail A; Foulkes S; Goga A; Oommen Jose A; Kruger G; Kalonji DJ; Lalloo N; Lombaard JJ; Lombard Koen A; Kany Luabeya A; Mngqibisa R; Petrick FG; Pitsi A; Tameris M; Thombrayil A; Vollgraaff PL; Cloney-Clark S; Zhu M; Bennett C; Albert G; Faust E; Plested JS; Fries L; Robertson A; Neal S; Cho I; Glenn GM; Shinde V;
    Lancet HIV; 2022 May; 9(5):e309-e322. PubMed ID: 35489376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.
    Falsey AR; Sobieszczyk ME; Hirsch I; Sproule S; Robb ML; Corey L; Neuzil KM; Hahn W; Hunt J; Mulligan MJ; McEvoy C; DeJesus E; Hassman M; Little SJ; Pahud BA; Durbin A; Pickrell P; Daar ES; Bush L; Solis J; Carr QO; Oyedele T; Buchbinder S; Cowden J; Vargas SL; Guerreros Benavides A; Call R; Keefer MC; Kirkpatrick BD; Pullman J; Tong T; Brewinski Isaacs M; Benkeser D; Janes HE; Nason MC; Green JA; Kelly EJ; Maaske J; Mueller N; Shoemaker K; Takas T; Marshall RP; Pangalos MN; Villafana T; Gonzalez-Lopez A;
    N Engl J Med; 2021 Dec; 385(25):2348-2360. PubMed ID: 34587382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study.
    Costa Clemens SA; Jepson B; Bhorat QE; Ahmad A; Akhund T; Aley PK; Bansal H; Bibi S; Kelly EJ; Khan M; Lambe T; Lombaard JJ; Matthews S; Pipolo Milan E; Olsson U; Ramasamy MN; Moura de Oliveira Paiva MS; Seegobin S; Shoemaker K; Szylak A; Villafana T; Pollard AJ; Green JA;
    Lancet Microbe; 2024 Aug; 5(8):100863. PubMed ID: 38878794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative effectiveness and duration of protection of ChAdOx1, CoronaVac, BNT162b2, mRNA-1273, and Ad26.COV2.S COVID-19 vaccines for symptomatic and hospitalized Mu, Delta, and Omicron: A test-negative case-control study.
    Paternina-Caicedo A; Quevedo DS; Ríos DS; Moyano D; Alvis-Guzmán N; Alviz-Zakzuk NR; Salcedo F; Moyano L; Ramírez-Suarez J; Smith AD; De la Hoz-Restrepo F
    Vaccine; 2023 Oct; 41(42):6291-6299. PubMed ID: 37679278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults.
    Raiser F; Davis M; Adelglass J; Cai MR; Chau G; Cloney-Clark S; Eickhoff M; Kalkeri R; McKnight I; Plested J; Zhu M; Dunkle LM;
    Vaccine; 2023 Sep; 41(41):5965-5973. PubMed ID: 37652823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines.
    Mueller-Enz M; Woopen C; Katoul Al Rahbani G; Haase R; Dunsche M; Ziemssen T; Akgün K
    Front Immunol; 2023; 14():1081933. PubMed ID: 37545513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
    Ramasamy MN; Minassian AM; Ewer KJ; Flaxman AL; Folegatti PM; Owens DR; Voysey M; Aley PK; Angus B; Babbage G; Belij-Rammerstorfer S; Berry L; Bibi S; Bittaye M; Cathie K; Chappell H; Charlton S; Cicconi P; Clutterbuck EA; Colin-Jones R; Dold C; Emary KRW; Fedosyuk S; Fuskova M; Gbesemete D; Green C; Hallis B; Hou MM; Jenkin D; Joe CCD; Kelly EJ; Kerridge S; Lawrie AM; Lelliott A; Lwin MN; Makinson R; Marchevsky NG; Mujadidi Y; Munro APS; Pacurar M; Plested E; Rand J; Rawlinson T; Rhead S; Robinson H; Ritchie AJ; Ross-Russell AL; Saich S; Singh N; Smith CC; Snape MD; Song R; Tarrant R; Themistocleous Y; Thomas KM; Villafana TL; Warren SC; Watson MEE; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Faust SN; Pollard AJ;
    Lancet; 2021 Dec; 396(10267):1979-1993. PubMed ID: 33220855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
    Emary KRW; Golubchik T; Aley PK; Ariani CV; Angus B; Bibi S; Blane B; Bonsall D; Cicconi P; Charlton S; Clutterbuck EA; Collins AM; Cox T; Darton TC; Dold C; Douglas AD; Duncan CJA; Ewer KJ; Flaxman AL; Faust SN; Ferreira DM; Feng S; Finn A; Folegatti PM; Fuskova M; Galiza E; Goodman AL; Green CM; Green CA; Greenland M; Hallis B; Heath PT; Hay J; Hill HC; Jenkin D; Kerridge S; Lazarus R; Libri V; Lillie PJ; Ludden C; Marchevsky NG; Minassian AM; McGregor AC; Mujadidi YF; Phillips DJ; Plested E; Pollock KM; Robinson H; Smith A; Song R; Snape MD; Sutherland RK; Thomson EC; Toshner M; Turner DPJ; Vekemans J; Villafana TL; Williams CJ; Hill AVS; Lambe T; Gilbert SC; Voysey M; Ramasamy MN; Pollard AJ; ; ;
    Lancet; 2021 Apr; 397(10282):1351-1362. PubMed ID: 33798499
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens.
    Upreti S; Samant M
    Pharm Res; 2022 Sep; 39(9):2119-2134. PubMed ID: 35773445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of available COVID-19 vaccines in reducing deaths and perspective for next generation vaccines and therapies to counter emerging viral variants: an update.
    Wahid M; Jawed A; Mandal RK; Areeshi MY; El-Shall NA; Mohapatra RK; Tuli HS; Dhama K; Pellicano R; Fagoonee S; Haque S
    Minerva Med; 2023 Oct; 114(5):683-697. PubMed ID: 37293890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heterologous prime-boost strategies for COVID-19 vaccines.
    Sapkota B; Saud B; Shrestha R; Al-Fahad D; Sah R; Shrestha S; Rodriguez-Morales AJ
    J Travel Med; 2022 May; 29(3):. PubMed ID: 34918097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S.
    Sadoff J; Gray G; Vandebosch A; Cárdenas V; Shukarev G; Grinsztejn B; Goepfert PA; Truyers C; Van Dromme I; Spiessens B; Vingerhoets J; Custers J; Scheper G; Robb ML; Treanor J; Ryser MF; Barouch DH; Swann E; Marovich MA; Neuzil KM; Corey L; Stoddard J; Hardt K; Ruiz-Guiñazú J; Le Gars M; Schuitemaker H; Van Hoof J; Struyf F; Douoguih M;
    N Engl J Med; 2022 Mar; 386(9):847-860. PubMed ID: 35139271
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial.
    Áñez G; Dunkle LM; Gay CL; Kotloff KL; Adelglass JM; Essink B; Campbell JD; Cloney-Clark S; Zhu M; Plested JS; Roychoudhury P; Greninger AL; Patel N; McGarry A; Woo W; Cho I; Glenn GM; Dubovsky F;
    JAMA Netw Open; 2023 Apr; 6(4):e239135. PubMed ID: 37099299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting.
    Rane MS; Robertson MM; Kulkarni SG; Frogel D; Gainus C; Nash D
    Vaccine; 2023 Jan; 41(4):989-998. PubMed ID: 36588007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.